Literature DB >> 22781280

Antibacterial activity of amphiphilic tobramycin.

Ramesh Dhondikubeer1, Smritilekha Bera, George G Zhanel, Frank Schweizer.   

Abstract

Amphiphilic aminoglycoside antimicrobials are an emerging class of new antibacterial agents with novel modes of action. Previous studies have shown that amphiphilic neomycin-B and kanamycin-A analogs restore potent antibacterial activity against Gram-positive neomycin-B- and kanamycin-A-resistant organisms. In this paper, we investigated the antibacterial properties of a series of amphiphilic tobramycin analogs. We prepared tobramycin-lipid conjugates, as well as tobramycin-peptide triazole conjugates, and studied their antibacterial activities against a panel of Gram-positive and Gram-negative bacterial strains, including isolates obtained from Canadian hospitals. Our results demonstrate that the antibacterial activity of amphiphilic tobramycin is greatly affected by the length and nature of the hydrophobic lipid tail, whereas the nature of the polycationic headgroup or the number of cationic charges appear to be less important. Replacement of the hydrophobic tail by a fluorinated lipid confers good activity against two Pseudomonas strains and reduces hemolytic activity. However, susceptibility studies in the presence of bovine serum albumin indicate that all amphiphilic tobramycin analogs are strongly protein-bound, leading to a typical four- to eight-fold increase in MIC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22781280     DOI: 10.1038/ja.2012.59

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  10 in total

1.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

2.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

Review 3.  Antibiotic Hybrids: the Next Generation of Agents and Adjuvants against Gram-Negative Pathogens?

Authors:  Ronald Domalaon; Temilolu Idowu; George G Zhanel; Frank Schweizer
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

4.  Topical Glycyrrhizin Is Therapeutic for Pseudomonas aeruginosa Keratitis.

Authors:  Sandamali A Ekanayaka; Sharon A McClellan; Ronald P Barrett; Linda D Hazlett
Journal:  J Ocul Pharmacol Ther       Date:  2017-12-13       Impact factor: 2.671

5.  Antifungal Amphiphilic Aminoglycosides.

Authors:  C-W T Chang; J Y Takemoto
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 6.  Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.

Authors:  Kristin J Labby; Sylvie Garneau-Tsodikova
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

7.  Characterization of ribosomal binding and antibacterial activities using two orthogonal high-throughput screens.

Authors:  Ada King; Derrick Watkins; Sunil Kumar; Nihar Ranjan; Changjun Gong; Jarred Whitlock; Dev P Arya
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

8.  Synthesis and Bioactivities of Kanamycin B-Derived Cationic Amphiphiles.

Authors:  Marina Y Fosso; Sanjib K Shrestha; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  J Med Chem       Date:  2015-12-01       Impact factor: 7.446

9.  Engineering persister-specific antibiotics with synergistic antimicrobial functions.

Authors:  Nathan W Schmidt; Stephanie Deshayes; Sinead Hawker; Alyssa Blacker; Andrea M Kasko; Gerard C L Wong
Journal:  ACS Nano       Date:  2014-08-18       Impact factor: 15.881

10.  Differential Effects of Linkers on the Activity of Amphiphilic Tobramycin Antifungals.

Authors:  Marina Y Fosso; Sanjib K Shrestha; Nishad Thamban Chandrika; Emily K Dennis; Keith D Green; Sylvie Garneau-Tsodikova
Journal:  Molecules       Date:  2018-04-13       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.